Marc E. Buyse

San Francisco

Contributor at Freelance

Featured in: Favicon

sagepub.com Favicon

tandfonline.com Favicon

jamanetwork.com Favicon

ascopubs.org Favicon

futuremedicine.com Favicon

future-science.com Favicon

picronline.org Favicon

jclinepi.com Favicon

thelancet.com + 2 more

Articles

Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials

May 21, 2024 | europeanurology.com | Praful Ravi |Wanling Xie |Marc E. Buyse |Susan Halabi |Philip W. Kantoff |Oliver Sartor
Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer

May 17, 2024 | europeanurology.com | Sabine D. Brookman-May |Janssen Research |Stephen J. Freedland |Spring House |Marc E. Buyse |Branko Miladinovic | +5 more

To read this article in full you will need to make a paymentSubscribe to European UrologyReferencesMetastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 35: 3097-3104ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era. Ann Oncol.
On Enhancing Clinical Trial Data Sharing

Oct 5, 2023 | jamanetwork.com | Marc E. Buyse |Statistical Bioinformatics

On Enhancing Clinical Trial Data Sharing Pharmaceutical Company Sharing of Individual-Participant Data Packages Ashley M. Hopkins, PhD; Natansh D. Modi, BPharm; Ahmad Y. Abuhelwa, PhD; Ganessan Kichenadasse, MD, PhD; Nicole M. Kuderer, MD; Gary H. Lyman, MD, MPH; Michael D. Wiese, PhD; Ross A. McKinnon, PhD; Frank W. Rockhold, PhD; Aaron Mann, BS; Andrew Rowland, PhD; Michael J.
A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration

Feb 4, 2023 | aaojournal.org | Marc E. Buyse
The Net Benefit of a treatment should take the correlation between benefits and harms into account

Mar 23, 2021 | jclinepi.com | Marc E. Buyse
Commentary on Bamat et al.

Jul 15, 2020 | journals.sagepub.com | Marc E. Buyse
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation | Journal of Clinical Oncology

Jun 17, 2020 | ascopubs.org | Marc E. Buyse
Common pitfalls in statistical analysis: Clinical versus statistical significance

Nov 18, 2019 | picronline.org | Marc E. Buyse
A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas | Future Oncology

Sep 12, 2019 | futuremedicine.com | Marc E. Buyse
Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study | Future Oncology

Sep 12, 2019 | futuremedicine.com | Marc E. Buyse

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →